Chinese COVID-19 Diagnostic Test Delivers Accurate Results in 40 Minutes Without Instrument for Less Than 70 Cents
By LabMedica International staff writers Posted on 31 Aug 2020 |
Illustration
Chinese researchers have developed a rapid CRISPR-based diagnostic for COVID-19 that delivers accurate results without the need for sophisticated equipment.
Researchers from the Xuzhou Medical University (Xuzhou, Jiangsu, China) harnessed the unique collateral activity of programmable CRISPR/Cas13a to develop CRISPR-COVID, a rapid and sensitive diagnostic for SARS-CoV-2 infection, and compared it to sequencing-based metagenomic and RT-PCR-based assays in a clinical cohort. CRISPR-COVID demonstrated a sensitivity level of near single copy and was highly specific without cross reacting to related pathogens. According to researchers, their study demonstrated that their CRISPR-based assay for COVID-19 offered shorter turn-around time and great diagnostic value, even in under-resourced settings without the need of thermal cyclers.
CRISPR-COVID takes only 40 minutes and requires no sophisticated thermo-cyclers, providing a valuable alternative to the conventional RT–PCR assay to circumvent the bottlenecks in assay turnaround time, equipment and reagent supplies for COVID-19 testing. The team noted that at research scale, the material costs of a CRISPR-COVID were less than USD 3.5, which could be dramatically reduced at production scale to less than 70 cents, making CRISPR-COVID a competitive alternative not only technologically but also financially.
Related Links:
Xuzhou Medical University
Researchers from the Xuzhou Medical University (Xuzhou, Jiangsu, China) harnessed the unique collateral activity of programmable CRISPR/Cas13a to develop CRISPR-COVID, a rapid and sensitive diagnostic for SARS-CoV-2 infection, and compared it to sequencing-based metagenomic and RT-PCR-based assays in a clinical cohort. CRISPR-COVID demonstrated a sensitivity level of near single copy and was highly specific without cross reacting to related pathogens. According to researchers, their study demonstrated that their CRISPR-based assay for COVID-19 offered shorter turn-around time and great diagnostic value, even in under-resourced settings without the need of thermal cyclers.
CRISPR-COVID takes only 40 minutes and requires no sophisticated thermo-cyclers, providing a valuable alternative to the conventional RT–PCR assay to circumvent the bottlenecks in assay turnaround time, equipment and reagent supplies for COVID-19 testing. The team noted that at research scale, the material costs of a CRISPR-COVID were less than USD 3.5, which could be dramatically reduced at production scale to less than 70 cents, making CRISPR-COVID a competitive alternative not only technologically but also financially.
Related Links:
Xuzhou Medical University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants